TC

20/09/2021 17:32

{I-bank focus}Morgan lowers Hepalink (09989) to HK$14.3

   Morgan Stanley lowered its target price for Hepalink (09989) to HK$14.3 from HK$15.1 and maintained its "overweight" rating.
  The research house said it cuts its EPS estimates by 8% for 2021, 6% for 2022, and 4% in 2023, and also reduce its forecasts over 2024-2030, following 1H21 earnings.

etnet榮獲HKEX Awards 2023 「最佳表現證券數據供應商」大獎► 了解詳情

人氣文章
財經新聞
評論
專題
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

觀落陰:什麼是觀落陰?人人都可參加地府自由行?遊地獄到底係點?

帶你探索全新主頁!輕鬆探索精選資訊!

全新etnet健康網購 賞維他命D3 (價值$108) 齊齊提升免疫力